产品
编 号：F743483
分子式：C34H45NO8
分子量：595.72
分子式：C34H45NO8
分子量：595.72
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1245653-57-9
产品详情
生物活性：
HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.
体内研究：
HAMI 3379 (0.025-0.4 mg/kg; ip) with 0.1-0.4 mg/kg significantly reduces the infarct volume and percentage increase in the ischemic/contralateral hemispheric ratio.HAMI3379 (0.1 mg/kg; ip) administered at 0 and 1 h after reperfusion reduces infarct volume, attenuated brain edema, reduced neurological score, and increased holdingangle. Animal Model:Male Sprague-Dawley rats (250-300 g) after MCAO
Dosage:0.025, 0.05, 0.1, 0.2, 0.4 mg/kg
Administration:IP
Result:Significantly reduced the infarct volume and percentage increase inthe ischemic/contralateral hemispheric ratio (an index ofbrain edema) with 0.1-0.4 mg/kg. Significantly reduced the neurological deficit score.
体外研究：
In a CysLT2 receptor reporter cell line, HAMI3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization with IC50 values of 3.8 nM and 4.4 nM respectively. HAMI3379 exhibits very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM). HAMI3379 does not exhibit any agonistic activity on both CysLT receptor cell lines.
HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.
体内研究：
HAMI 3379 (0.025-0.4 mg/kg; ip) with 0.1-0.4 mg/kg significantly reduces the infarct volume and percentage increase in the ischemic/contralateral hemispheric ratio.HAMI3379 (0.1 mg/kg; ip) administered at 0 and 1 h after reperfusion reduces infarct volume, attenuated brain edema, reduced neurological score, and increased holdingangle. Animal Model:Male Sprague-Dawley rats (250-300 g) after MCAO
Dosage:0.025, 0.05, 0.1, 0.2, 0.4 mg/kg
Administration:IP
Result:Significantly reduced the infarct volume and percentage increase inthe ischemic/contralateral hemispheric ratio (an index ofbrain edema) with 0.1-0.4 mg/kg. Significantly reduced the neurological deficit score.
体外研究：
In a CysLT2 receptor reporter cell line, HAMI3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization with IC50 values of 3.8 nM and 4.4 nM respectively. HAMI3379 exhibits very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM). HAMI3379 does not exhibit any agonistic activity on both CysLT receptor cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备